<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968264</url>
  </required_header>
  <id_info>
    <org_study_id>TOF-LIFE 2.0 2015-06-11</org_study_id>
    <nct_id>NCT02968264</nct_id>
  </id_info>
  <brief_title>Tetralogy of Fallot for Life</brief_title>
  <acronym>TOF-LIFE</acronym>
  <official_title>Tetralogy of Fallot for Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to conduct a prospective multi-centre international inception cohort study with an
      enrollment goal of 3,000 TOF patients and 2 year follow-up post-repair. The proposed sample
      size and methodology will result in statistically powerful results to allow for
      evidence-based change to current TOF surgical practices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Tetralogy of Fallot (TOF) is the most common cyanotic heart defect consisting of
      7-10% of all congenital heart disease with an estimated annual global incidence rate of
      38,000. It is fatal if untreated; only 50% of patients are alive at 1 year of age. Surgery
      has dramatically improved the survival so that &gt;95% of repaired TOF children are alive by one
      year. The initial justified enthusiasm for the benefit of surgical therapy are now tempered
      by the findings of late sudden cardiac death secondary to right ventricular (RV) dysfunction.
      The original trans-ventricular/trans-annular patching repair results in significant pulmonary
      insufficiency which leads to RV dilation, subsequent functional tricuspid regurgitation,
      atrial arrhythmias, and eventual RV failure and ventricular arrhythmias. In attempt to break
      this cycle, an increasing number of patients are undergoing late pulmonary valve
      implantation.

      Recognizing that the RV adapts to stress signals has led to the idea that leaving mixed
      residual stenosis and regurgitation may yield to an adaptive change that limits RV dilation
      while still allowing for adequate cardiac output. Early attempts to limit pulmonary
      insufficiency and RV damage involve minimal trans-annular patching or complete annulus
      preservation (AP). Emerging data suggest that patients with a mixed lesion have improved
      survival, so that 96.6% are alive at 25-years in comparison to 85-90% survival for the
      conventional technique.

      Preliminary Data: A review of data comparing AP to TAP repair at our institution (n=185, AP
      repair=124, TAP=61) demonstrated that at 10-15 year follow-up those who received an AP repair
      had smaller RV volumes and pulmonary regurgitant jet width. They were also seen to have
      improved exercise capacity as measure by VO2 max tests. The AP technique also has been seen
      to significantly decrease the risk of reoperation in comparison to TAP, 11% and 29%
      respectively.

      Current Problem: Although trans-ventricular VSD closure along with a TAP is known to result
      in increased risk of long-term morbidity and mortality, it continues to be the predominant
      repair strategy implemented globally according to STS/EACTS databases. Reasons for this are:

        -  Trans-ventricular/TAP approach is technically easier than annulus preservation, which
           often requires multiple pump runs

        -  There is a fear of leaving too much obstruction

        -  High quality evidence supporting one approach over the other is lacking.

      Gaps in Literature

        1. Most data on the impact of surgical strategy emerge from single centre experiences that
           are retrospective and based on small patient population. This makes the results
           difficult to standardize to the general TOF population.

        2. Retrospective registry data published by STS and EACTS omit many crucial surgical and
           clinical variables that can potentially impact outcomes.

        3. None of the current evidence are based on anatomically matched/adjusted patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>RV physiology and morphology</measure>
    <time_frame>2 years post-repair</time_frame>
    <description>To determine the association between baseline morphology, surgical repair technique (various surgical strategies for VSD closure and managing the RVOT), and RV physiology and morphology at 2 years obtained from echocardiogram studies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing various palliation procedures and surgical repair strategies</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the pattern of palliation procedures (BT shunt, RVOT stent, or balloon dilation), surgical repair strategy (staged versus primary repair), and surgical repair technique (AP, minimal TAP, standard TAP) at participating centres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality rate</measure>
    <time_frame>30 days and 2 years after repair</time_frame>
    <description>To determine the 30-day and 2 year cardiovascular mortality rate (for equivalent patients) after primary and staged repair.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of palliation failure</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the rate of palliation failure following various palliation techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of palliation procedures on cardiac morphology</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the possible effect of palliative procedures (BT shunts, balloon dilation, stent insertion) on cardiac morphology (growth of the infundibular chamber, the pulmonary annulus and PA branches' diameter) and subsequent repair technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative restrictive physiology</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the relationship between repair technique/strategy and prevalence of postoperative restrictive physiology as defined by the presence of antegrade flow in pulmonary artery during atrial contraction on echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac re-interventions</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the relationship between TOF repair strategy/technique on the incidence and prevalence of cardiac re-interventions (e.g. pulmonary valve implantation, RVOT stent insertion or balloon dilatation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV physiology and morphology following TOF pulmonary atresia repair</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the right ventricular morphological and physiological adaptations to severe pulmonary stenosis or regurgitation using repaired TOF pulmonary atresia as a model. For example RV/LV end diastolic and systolic diameter ratio. RV and LV wall thickness relation to outflow gradient obtained by echocardiogram studies.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Tetralogy of Fallot</condition>
  <condition>Congenital Heart Disease</condition>
  <condition>Congenital Heart Defect</condition>
  <arm_group>
    <arm_group_label>TOF participants</arm_group_label>
    <description>Tetralogy of fallot patients at any age</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        TOF patients of any age undergoing their first cardiac intervention. Please refer to the
        eligibility criteria for more details.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TOF with RVOT stenosis. TOF is defined as anterio-cephalad deviation of the
             ventricular outlet septum with no more than 50% aortic override and a single outflow
             VSD.

          -  TOF with pulmonary atresia and confluent pulmonary arteries.

          -  Admitted with intent to treat (i.e. patient planned to undergo a primary or staged
             repair).

          -  Patients with coronary artery anomalies, right aortic arch, and 22q11 deletion may be
             included

        Exclusion Criteria:

          -  TOF with absent pulmonary valve

          -  Other major cardiac anomalies such as AVSD, multiple VSDs, right atrial isomerism, and
             MAPCAs. In this instance, the definition of MAPCAs does not include dilated bronchial
             collateral arteries.

          -  Unbalanced ventricles precluding biventricular repair

          -  Major genetic abnormalities/syndromes e.g. trisomy 13,18, and 21

          -  Major extra cardiac anomalies e.g. diaphragmatic hernia, omphalocele, absent sternum,
             cerebral palsy

          -  Infective endocarditis as an indication for intra-cardiac repair

          -  Stroke in the last 30 days prior to palliation or intra-cardiac repair

          -  Known diagnosis of HIV or hepatitis B

          -  Any previous cardiac procedures

          -  Patient's circumstance that precludes completion of follow-up telephone call and/or
             obtaining information from the 2-year cardiology follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glen Van Arsdell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Whitlock, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Copland, CCRA</last_name>
    <email>tof.life@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Hussain, MD</last_name>
    <email>tof.life@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Wiess</last_name>
      <email>cw2780@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Emile Bacha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid King</last_name>
    </contact>
    <contact_backup>
      <last_name>Karin du Plessis</last_name>
    </contact_backup>
    <investigator>
      <last_name>Yves D'Udekem, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Balmer, BSc</last_name>
    </contact>
    <investigator>
      <last_name>Glen Van Arsdell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Mertens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhua Luo, MD</last_name>
    </contact>
    <investigator>
      <last_name>An Qi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Liu, Coordinator</last_name>
      <email>904245589@qq.com</email>
    </contact>
    <investigator>
      <last_name>Richard Hua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Women and Children's Medical Center</name>
      <address>
        <city>Guangdong</city>
        <zip>510623</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidan Chen, MD</last_name>
      <email>chenweidan2003@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinxin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Cardiovascular Institute</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>JiMei Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Medical Centre</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renjie Hu, Coordinator</last_name>
      <email>hurenjie1988@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Haibo Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiaquan Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fortis Escorts Heart Institute</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110025</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jahanvi Sharma</last_name>
    </contact>
    <investigator>
      <last_name>Krishna Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kokilaben Dhirubhai Ambani Hospital &amp; Medical Research Institutev</name>
      <address>
        <city>Mumbai</city>
        <zip>400 053</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamlesh Sankpal</last_name>
    </contact>
    <investigator>
      <last_name>Suresh Rao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tae Jin Yun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manmohan Cardiothoracic Vascular and Transplant Center</name>
      <address>
        <city>Kathmandu</city>
        <zip>977</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhagawan Koirala</last_name>
    </contact>
    <investigator>
      <last_name>Bhagawan Koirala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academician E.N. Meshalkin Research</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Arkhipov, MD, PhD</last_name>
      <email>a_arkhipov@meshalkin.ru</email>
    </contact>
    <investigator>
      <last_name>Alexander Bogachev-Prokophiev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz University Hospital</name>
      <address>
        <city>Jeddah</city>
        <state>Makkah</state>
        <zip>21589</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ragab Debis</last_name>
    </contact>
    <investigator>
      <last_name>Osman Al-Radi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital and Research Centre - Jeddah</name>
      <address>
        <city>Jeddah</city>
        <zip>21499</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Osman Al-Radi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Cardiac Center - Ukraine</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Borodinova, MD</last_name>
      <email>o.blajchuk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Illya Yemets, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Nepal</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tof-life.com</url>
    <description>TOF LIFE study website</description>
  </link>
  <reference>
    <citation>Sarris GE, Comas JV, Tobota Z, Maruszewski B. Results of reparative surgery for tetralogy of Fallot: data from the European Association for Cardio-Thoracic Surgery Congenital Database. Eur J Cardiothorac Surg. 2012 Nov;42(5):766-74; discussion 774. doi: 10.1093/ejcts/ezs478.</citation>
    <PMID>23087090</PMID>
  </reference>
  <reference>
    <citation>Al Habib HF, Jacobs JP, Mavroudis C, Tchervenkov CI, O'Brien SM, Mohammadi S, Jacobs ML. Contemporary patterns of management of tetralogy of Fallot: data from the Society of Thoracic Surgeons Database. Ann Thorac Surg. 2010 Sep;90(3):813-9; discussion 819-20. doi: 10.1016/j.athoracsur.2010.03.110.</citation>
    <PMID>20732501</PMID>
  </reference>
  <reference>
    <citation>Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, Rosenthal M, Nakazawa M, Moller JH, Gillette PC, Webb GD, Redington AN. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000 Sep 16;356(9234):975-81.</citation>
    <PMID>11041398</PMID>
  </reference>
  <reference>
    <citation>d'Udekem Y, Galati JC, Rolley GJ, Konstantinov IE, Weintraub RG, Grigg L, Ramsay JM, Wheaton GR, Hope S, Cheung MH, Brizard CP. Low risk of pulmonary valve implantation after a policy of transatrial repair of tetralogy of Fallot delayed beyond the neonatal period: the Melbourne experience over 25 years. J Am Coll Cardiol. 2014 Feb 18;63(6):563-8. doi: 10.1016/j.jacc.2013.10.011. Epub 2013 Oct 30.</citation>
    <PMID>24513776</PMID>
  </reference>
  <reference>
    <citation>Pondorfer P YT, Cheung M, Ashburn D, Manlhiot C, McCrindle B, Mertens L, Grosse-Wortmann L, Redington A, Van Arsdell G. Abstract 18833: Annulus Preservation Strategy Improves Late Outcomes in Tetralogy of Fallot: An Anatomical Equivalency Study. Circulation. 2014;130:A18833.</citation>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

